Company / EPS (Diluted)
Voyager Therapeutics, Inc. EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
$2.97
FY2025
5-year range
-$1.89 / $2.97
FY2021-FY2025
Trend
+345.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
EPS (Diluted) changed +345% YoY in FY2025, a notable deviation from the 9-year average annual change of +8%.
Based on SEC 10-K filings.
2.97 in FY2025 with a 3-year CAGR of +44.7%.
Improved from $-1.89 to $2.97 over the past 2 years.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- +44.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, eps (diluted) increased 345.5% year-over-year.
- Peak eps (diluted) was recorded in FY2016.
- Lowest eps (diluted) in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score 0.34 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.97 | +345.5% |
| FY2024 | -$1.21 | +36.0% |
| FY2023 | -$1.89 | -292.9% |
| FY2022 | $0.98 | +181.0% |
| FY2021 | -$1.21 | +56.0% |
| FY2020 | -$2.75 | -4.2% |
| FY2019 | -$2.64 | -66.0% |
| FY2018 | -$1.59 | -117.4% |
| FY2017 | $9.14 | -67.2% |
| FY2016 | $27.83 | -98.3% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026